Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary

Pacira BioSciences participates in fireside chat at H.C. Wainwright Conference

Positive

• Positive: Increased visibility and investor engagement through participation in the conference

Negative

• None.

TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25^th Annual Global Investment Conference.  The pre-recorded audio of the virtual event can be accessed beginning Monday, September 11^th at 7:00AM ET by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.